BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma

This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of immunotherapy in patients with multiple myeloma, while remaining safe and well-tolerated. Patients will be randomly assigned to one of four intervention groups or a control group. The intervention groups will either follow a ketogenic diet (less than 10% of calories from carbohydrates) or receive oral supplementation with deltaG® Ketone Monoester Performance \[(R)-3-hydr

Trial Details

NCT ID
NCT07564219
Phase
NA
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Ketogenic diet
  • Ketogenic Drinks
Locations (sample)
  • Hamburg, Free and Hanseatic City of Hamburg, Germany|53.55073,9.99302

Key Eligibility Criteria

  • Multiple Myeloma with indication for CAR-T cell therapy with Ciltacabtagene autoleucel (target antigen: BCMA) or a BCMA-directed bispecific antibod…
  • Age ≥18 years on the day the informed consent is signed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →